Acromegaly: The Research and Practical Value of Noninvasive Hemodynamic Assessments
Acromegaly
/ physiopathology
Adult
Blood Flow Velocity
Cardiac Output
Cardiography, Impedance
Case-Control Studies
Female
Heart Rate
Hemodynamics
/ physiology
Humans
Hypertension
/ physiopathology
Male
Middle Aged
Prospective Studies
Stroke Volume
Vascular Remodeling
Vascular Resistance
Vascular Stiffness
Ventricular Remodeling
acromegaly
arterial
cardiovascular complications
hemodynamics instability
impedance cardiography
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
10
2021
accepted:
20
12
2021
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
3
3
2022
Statut:
epublish
Résumé
Arterial hypertension (AH) that accompanies acromegaly (AC) may lead to cardiovascular dysfunction. Such consequences may be detected with impedance cardiography (ICG), which is a noninvasive method of hemodynamic assessment. Early detection of subclinical hemodynamic alterations in AC patients may be crucial for optimizing treatment and preventing cardiovascular remodeling. The purpose of this study was to identify the hemodynamic parameters of the cardiovascular system that differentiate patients with AC from those in the control group (CG), with a particular emphasis on potential targets for medical therapy. This observational, prospective, clinical study involved a comparative analysis of 33 AC patients with no significant comorbidities and the controls selected Both the AC group and the CG had well-controlled AH (mean blood pressure of 121/77 mmHg and 119/76 mmHg, respectively). In terms of baseline characteristics, the AC group was characterized by a higher hear rate and lower creatinine levels than the CG (76.2 bpm vs. 66.8 bpm [p = 0.001] and 0.755 mg/dL vs. 0.850 mg/dL [p = 0.035], respectively). ICG assessment of AC patients and CG patients showed the former to have higher heart rates (73.5 bpm vs. 65.2 bpm; p = 0.003), lower SI (43.8 mL/m Even with well-controlled hypertension, AC is associated with a high TFC, increased heart rate, and decreased indices of cardiac contractility. Hemodynamic changes in AC patients may be detected with the modern, noninvasive diagnostic tool, ICG.
Sections du résumé
Background
Arterial hypertension (AH) that accompanies acromegaly (AC) may lead to cardiovascular dysfunction. Such consequences may be detected with impedance cardiography (ICG), which is a noninvasive method of hemodynamic assessment. Early detection of subclinical hemodynamic alterations in AC patients may be crucial for optimizing treatment and preventing cardiovascular remodeling. The purpose of this study was to identify the hemodynamic parameters of the cardiovascular system that differentiate patients with AC from those in the control group (CG), with a particular emphasis on potential targets for medical therapy.
Methods
This observational, prospective, clinical study involved a comparative analysis of 33 AC patients with no significant comorbidities and the controls selected
Results
Both the AC group and the CG had well-controlled AH (mean blood pressure of 121/77 mmHg and 119/76 mmHg, respectively). In terms of baseline characteristics, the AC group was characterized by a higher hear rate and lower creatinine levels than the CG (76.2 bpm vs. 66.8 bpm [p = 0.001] and 0.755 mg/dL vs. 0.850 mg/dL [p = 0.035], respectively). ICG assessment of AC patients and CG patients showed the former to have higher heart rates (73.5 bpm vs. 65.2 bpm; p = 0.003), lower SI (43.8 mL/m
Conclusions
Even with well-controlled hypertension, AC is associated with a high TFC, increased heart rate, and decreased indices of cardiac contractility. Hemodynamic changes in AC patients may be detected with the modern, noninvasive diagnostic tool, ICG.
Identifiants
pubmed: 35116005
doi: 10.3389/fendo.2021.793280
pmc: PMC8805171
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
793280Informations de copyright
Copyright © 2022 Jurek, Krzesiński, Gielerak, Witek, Zieliński, Kazimierczak, Wierzbowski, Banak and Uziębło-Życzkowska.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Endocrinol (Oxf). 2000 May;52(5):549-55
pubmed: 10792333
Congest Heart Fail. 2004 Mar-Apr;10(2 Suppl 2):11-3
pubmed: 15073479
J Clin Endocrinol Metab. 2000 Jan;85(1):179-82
pubmed: 10634384
Clin Endocrinol (Oxf). 2001 Feb;54(2):137-54
pubmed: 11207626
Am J Med. 2002 Jun 1;112(8):610-6
pubmed: 12034409
Endocr Rev. 2003 Jun;24(3):272-7
pubmed: 12788799
Endocr Rev. 1996 Oct;17(5):423-80
pubmed: 8897021
Pituitary. 2001 Sep;4(4):239-49
pubmed: 12501974
Diabetes Care. 2019 Jan;42(Suppl 1):S13-S28
pubmed: 30559228
Am J Cardiol. 1995 May 15;75(15):1042-7
pubmed: 7747686
N Engl J Med. 2006 Dec 14;355(24):2558-73
pubmed: 17167139
J Clin Endocrinol Metab. 2009 May;94(5):1509-17
pubmed: 19208732
J Clin Endocrinol Metab. 2013 Jan;98(1):E51-9
pubmed: 23162101
Pituitary. 2011 Sep;14(3):231-5
pubmed: 21161601
Nat Rev Endocrinol. 2018 Sep;14(9):552-561
pubmed: 30050156
J Clin Endocrinol Metab. 2016 Nov;101(11):3997-4004
pubmed: 27428551
Pituitary. 2017 Feb;20(1):46-62
pubmed: 28224405
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
Clin Endocrinol (Oxf). 2003 Feb;58(2):169-76
pubmed: 12580932
Pol Merkur Lekarski. 2015 Dec;39(234):352-8
pubmed: 26802686
J Clin Endocrinol Metab. 2008 Jul;93(7):2639-46
pubmed: 18445662
Am Heart J. 1980 Jul;100(1):41-52
pubmed: 6446234
J Clin Endocrinol Metab. 2007 Nov;92(11):4271-7
pubmed: 17785352
Endocr Rev. 2004 Feb;25(1):102-52
pubmed: 14769829
J Clin Invest. 2009 Nov;119(11):3189-202
pubmed: 19884662
J Clin Endocrinol Metab. 2000 Jan;85(1):193-9
pubmed: 10634386
J Clin Endocrinol Metab. 2004 Feb;89(2):667-74
pubmed: 14764779
Nouv Presse Med. 1977 Feb 19;6(7):562
pubmed: 840636
Pituitary. 2003;6(4):203-7
pubmed: 15237931
J Nucl Med. 1995 Feb;36(2):196-201
pubmed: 7830112
J Am Soc Hypertens. 2015 Sep;9(9):680-9
pubmed: 26233299
Clin Endocrinol (Oxf). 2010 Feb;72(2):203-8
pubmed: 19473180
Front Endocrinol (Lausanne). 2020 Jun 24;11:418
pubmed: 32670201
Eur J Endocrinol. 2011 Jun;164(6):877-84
pubmed: 21464140
Kardiol Pol. 2009 Jan;67(1):65-71
pubmed: 19253194
Eur J Endocrinol. 2010 Jun;162(6):1035-42
pubmed: 20356933
Clin Endocrinol (Oxf). 2000 Oct;53(4):445-51
pubmed: 11012569
Pituitary. 2012 Dec;15(4):539-51
pubmed: 22116639
Pituitary. 1999 Jun;2(1):29-41
pubmed: 11081170
Acta Med Scand. 1988;223(4):337-43
pubmed: 3369314
J Hum Hypertens. 2001 Sep;15(9):601-5
pubmed: 11550105
J Endocrinol Invest. 2006 Jun;29(6):544-50
pubmed: 16840833
Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1326-32
pubmed: 11701449
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Am J Hypertens. 2005 Feb;18(2 Pt 2):73S-81S
pubmed: 15752936
Clin Endocrinol (Oxf). 1998 Jul;49(1):101-6
pubmed: 9797853
J Clin Endocrinol Metab. 1997 Apr;82(4):1047-53
pubmed: 9100571